201 related articles for article (PubMed ID: 23546553)
1. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Henry NL; Skaar TC; Dantzer J; Li L; Kidwell K; Gersch C; Nguyen AT; Rae JM; Desta Z; Oesterreich S; Philips S; Carpenter JS; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2013 Apr; 138(3):807-16. PubMed ID: 23546553
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Kidwell KM; Harte SE; Hayes DF; Storniolo AM; Carpenter J; Flockhart DA; Stearns V; Clauw DJ; Williams DA; Henry NL
Cancer; 2014 Aug; 120(16):2403-11. PubMed ID: 24802413
[TBL] [Abstract][Full Text] [Related]
3. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Henry NL; Azzouz F; Desta Z; Li L; Nguyen AT; Lemler S; Hayden J; Tarpinian K; Yakim E; Flockhart DA; Stearns V; Hayes DF; Storniolo AM
J Clin Oncol; 2012 Mar; 30(9):936-42. PubMed ID: 22331951
[TBL] [Abstract][Full Text] [Related]
4. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
5. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Henry NL; Chan HP; Dantzer J; Goswami CP; Li L; Skaar TC; Rae JM; Desta Z; Khouri N; Pinsky R; Oesterreich S; Zhou C; Hadjiiski L; Philips S; Robarge J; Nguyen AT; Storniolo AM; Flockhart DA; Hayes DF; Helvie MA; Stearns V
Br J Cancer; 2013 Oct; 109(9):2331-9. PubMed ID: 24084768
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
Hertz DL; Douglas JA; Miller RM; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Support Care Cancer; 2022 Oct; 30(10):8059-8067. PubMed ID: 35776183
[TBL] [Abstract][Full Text] [Related]
10. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Goss PE; Ingle JN; Pritchard KI; Ellis MJ; Sledge GW; Budd GT; Rabaglio M; Ansari RH; Johnson DB; Tozer R; D'Souza DP; Chalchal H; Spadafora S; Stearns V; Perez EA; Liedke PE; Lang I; Elliott C; Gelmon KA; Chapman JA; Shepherd LE
J Clin Oncol; 2013 Apr; 31(11):1398-404. PubMed ID: 23358971
[TBL] [Abstract][Full Text] [Related]
11. Effects of
Dempsey JM; Kidwell KM; Gersch CL; Pesch AM; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; Hertz DL
Pharmacogenomics; 2019 Jun; 20(8):571-580. PubMed ID: 31190621
[No Abstract] [Full Text] [Related]
12. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
13. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
[TBL] [Abstract][Full Text] [Related]
14. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
16. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
18. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL
Oncologist; 2016 May; 21(5):539-46. PubMed ID: 27009936
[TBL] [Abstract][Full Text] [Related]
20. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
